A strong predictor in carcinoma of the breast.

Am J Clin Pathol

Published: November 1998

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/110.5.695aDOI Listing

Publication Analysis

Top Keywords

strong predictor
4
predictor carcinoma
4
carcinoma breast
4
strong
1
carcinoma
1
breast
1

Similar Publications

Background: Deep vein thrombosis (DVT) of the lower limb is a significant clinical challenge with the potential for recurrence, which can lead to increased morbidity and reduced quality of life.

Methods: A retrospective case-control study was conducted involving 367 patients diagnosed with lower limb DVT from June 2020 to June 2023. Patients were categorized into a recurrence group ( = 121) and a non-recurrence group ( = 246) based on DVT occurrence.

View Article and Find Full Text PDF

Background: Nursing students represent a unique group that faces specific stressors. One of these stressors is social appearance anxiety, which can adversely affect the quality of life. Personality traits are strong predictors of coping with stress and anxiety.

View Article and Find Full Text PDF

Functionally-informed fine-mapping identifies genetic variants linking increased CHD1L expression and HIV restriction in monocytes.

Sci Rep

January 2025

Sexually Transmitted and Bloodborne Infections Surveillance and Molecular Epidemiology, Sexually Transmitted and Bloodborne Infections Division at the JC Wilt Infectious Diseases Research Centre, National Microbiology Laboratories, Public Health Agency of Canada, Winnipeg, MB, R3E 3L5, Canada.

Human Immunodeficiency Virus Type 1 (HIV) set-point viral load is a strong predictor of disease progression and transmission risk. A recent genome-wide association study in individuals of African ancestries identified a region on chromosome 1 significantly associated with decreased HIV set-point viral load. Knockout of the closest gene, CHD1L, enhanced HIV replication in vitro in myeloid cells.

View Article and Find Full Text PDF

Colorectal carcinoma brain metastases (n=60) were studied using next-generation sequencing and immunohistochemistry. RAS and BRAF mutations were detected in 58.2% and 7.

View Article and Find Full Text PDF

Background: Breast cancer is the most common malignant tumor among women, with an increasing incidence each year. The subtypes of human epidermal growth factor receptor 2 (HER2)-negative breast cancer, classified as HER2-low and HER2-zero based on HER2 receptor expression, show differences in clinical characteristics, therapeutic approaches, and prognoses. Distinguishing between these subtypes is clinically valuable as it can impact treatment strategies, including the use of next-generation antibody-drug conjugates (ADCs) targeting HER2-low tumors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!